Lee's Pharmaceutical Holdings（LPCU.F）株式概要リーズファーマシューティカルホールディングスは投資持株会社で、主に中華人民共和国で医薬品の開発、製造、マーケティング、販売を行っている。 詳細LPCU.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績3/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より97.6%で取引されている 過去1年間で収益は55.1%増加しました リスク分析株式の流動性は非常に低い 過去5年間で収益は年間43.2%減少しました。 財務結果に影響を与える大きな一時的項目 不安定な配当実績 すべてのリスクチェックを見るLPCU.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.1935.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-140m2b2016201920222025202620282031Revenue HK$1.5bEarnings HK$104.4mAdvancedSet Fair ValueView all narrativesLee's Pharmaceutical Holdings Limited 競合他社bioteSymbol: NasdaqGM:BTMDMarket cap: US$71.1mStablecoin DevelopmentSymbol: NYSEAM:SDEVMarket cap: US$63.2mOramed PharmaceuticalsSymbol: NasdaqCM:ORMPMarket cap: US$162.5mSIGA TechnologiesSymbol: NasdaqGM:SIGAMarket cap: US$335.7m価格と性能株価の高値、安値、推移の概要Lee's Pharmaceutical Holdings過去の株価現在の株価HK$0.1952週高値HK$0.1952週安値HK$0.19ベータ0.551ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-82.54%最新ニュースお知らせ • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025最新情報をもっと見るRecent updatesお知らせ • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Aug 02Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong KongLee's Pharmaceutical Holdings Limited announced that on 15 July 2024, the first patient has been enrolled in a Phase I clinical trial to receive AU409 at Queen Mary Hospital, Hong Kong. This trial focuses on patients with advanced hepatocellular carcinoma who have previously failed standard first-line treatment. AU409 is a novel drug discovered and owned by Auransa Inc. ("A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients who failed Standard Treatment" is led by Principal Investigator Dr. Chi Leung Chiang, MD. The primary objectives are to determine the maximum tolerated dose and recommended Phase II dose, as well as to characterise the safety and tolerability of AU409. Secondary objectives include assessing the pharmacokinetics and preliminary anti-tumor activity of AU409. AU409 is a novel drug discovered and owned by Auransa Inc. ("Auransa"), and is manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly owned subsidiary of the Group, in compliance with the Good Manufacturing Practice regulations set by the U.S. Food and Drug Administration. This Phase I clinical trial marks the first-in-human study in Asia and is expected to conclude by the second quarter of 2025. The results of this study will be used for China's new drug registration purpose.お知らせ • Jul 02Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive DirectorThe board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023.お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024. Agenda: To consider and approve the final dividend in respect of the year ended 31 December 2023 of HK1.0 cent per share in an aggregate amount of HK$5,888,000; and to consider other matters.お知らせ • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.お知らせ • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024お知らせ • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.お知らせ • Aug 22+ 1 more updateLee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023Lee's Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Group is expected to record an unaudited net profit attributable to the Shareholders of between HKD 12 million and HKD 17 million for the six months ended 30 June 2023 as compared with approximately HKD 28 million recorded for the six months ended 30 June 2022.お知らせ • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023お知らせ • May 18Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive DirectorLee's Pharmaceutical Holdings Limited approved to appoint Ms. Cheang Yee Wah, Eva as the independent non-executive director of the Company, at the AGM held on 17 May 2023.お知らせ • Jan 20Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug ListLee's Pharmaceutical Holdings Limited announce that the Group's commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the "NRDL") issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group's Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordabilityand accessibility thereof among patients in rare disease and mental health areas.株主還元LPCU.FUS PharmaceuticalsUS 市場7D0%0.1%1.6%1Yn/a40.5%28.2%株主還元を見る業界別リターン: LPCU.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: LPCU.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is LPCU.F's price volatile compared to industry and market?LPCU.F volatilityLPCU.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.8%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.0%安定した株価: LPCU.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のLPCU.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19941,036n/awww.leespharm.com投資持株会社であるLee's Pharmaceutical Holdings Limitedは、主に中華人民共和国において医薬品の開発、製造、マーケティング、販売を行っている。心臓血管、女性の健康、小児科、希少疾患、腫瘍、皮膚科、産科を含む様々な疾患分野に注力している。独自製品・ジェネリック製品事業、ライセンスイン製品事業を通じて事業を展開している。自社開発品・ジェネリック医薬品事業では、血栓・深部静脈血栓症治療薬ナドロパリンカルシウム注射液、リバラシン、ウイルス感染症治療薬ヤラフェロン、止血剤スローナーゼ、角膜潰瘍治療薬アイプロトール、肺動脈性肺高血圧症治療薬トレプロスチニル注射液、深部静脈血栓症治療薬フォンダパリヌクスナトリウム注射液、尿素サイクル異常症治療薬フェニル酪酸ナトリウム顆粒などの自社開発品・ジェネリック医薬品を製造・販売している。ライセンス品事業では、カルニチン欠乏症治療剤Carnitene、化学療法による悪心・嘔吐治療剤Sancuso、腎移植における免疫抑制治療剤Bredinin、鼓膜切開チューブを伴う急性中耳炎治療剤Centraxal Plus、口腔粘膜炎の疼痛治療剤Episil、鉄欠乏性貧血治療剤Ferplex、胃潰瘍・胃炎治療剤Gaslon Nなどのライセンス品を取り扱っている。また、外陰部膣萎縮症の治療薬Intrarosa、成人の統合失調症や双極Ⅰ型障害に伴う興奮の治療薬Adasuve、尿失禁の治療薬Mictonorm、ステージⅢおよびⅣのホジキン病の治療薬Natulan、オメガ3酸エチルエステルの治療薬Omacorも提供している；高血圧症治療薬ZanidipとRasilez、術後疼痛管理薬Readyfusor、筋萎縮性側索硬化症治療薬Teglutik、不眠症／うつ病治療薬Trittico、尿路・呼吸器感染症治療薬Unidrox、プロバイオティクスDicoflorとVSL#3、局所鎮痛薬Zingo。同社は1994年に設立され、香港の沙田に本社を置いている。もっと見るLee's Pharmaceutical Holdings Limited 基礎のまとめLee's Pharmaceutical Holdings の収益と売上を時価総額と比較するとどうか。LPCU.F 基礎統計学時価総額US$111.51m収益（TTM）US$12.51m売上高(TTM)US$183.80m8.9xPER（株価収益率0.6xP/SレシオLPCU.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計LPCU.F 損益計算書（TTM）収益HK$1.44b売上原価HK$673.63m売上総利益HK$762.81mその他の費用HK$665.01m収益HK$97.81m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）0.17グロス・マージン53.10%純利益率6.81%有利子負債／自己資本比率12.6%LPCU.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.2%現在の配当利回り28%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/17 05:47終値2025/11/20 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Lee's Pharmaceutical Holdings Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Chu WangCitigroup IncJun Zhou LiEverbright Securities Co. Ltd.Yue-Kwong LuiJefferies LLC3 その他のアナリストを表示
お知らせ • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.
お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.
お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.
お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.
お知らせ • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.
お知らせ • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.
お知らせ • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Aug 02Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong KongLee's Pharmaceutical Holdings Limited announced that on 15 July 2024, the first patient has been enrolled in a Phase I clinical trial to receive AU409 at Queen Mary Hospital, Hong Kong. This trial focuses on patients with advanced hepatocellular carcinoma who have previously failed standard first-line treatment. AU409 is a novel drug discovered and owned by Auransa Inc. ("A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients who failed Standard Treatment" is led by Principal Investigator Dr. Chi Leung Chiang, MD. The primary objectives are to determine the maximum tolerated dose and recommended Phase II dose, as well as to characterise the safety and tolerability of AU409. Secondary objectives include assessing the pharmacokinetics and preliminary anti-tumor activity of AU409. AU409 is a novel drug discovered and owned by Auransa Inc. ("Auransa"), and is manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly owned subsidiary of the Group, in compliance with the Good Manufacturing Practice regulations set by the U.S. Food and Drug Administration. This Phase I clinical trial marks the first-in-human study in Asia and is expected to conclude by the second quarter of 2025. The results of this study will be used for China's new drug registration purpose.
お知らせ • Jul 02Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive DirectorThe board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023.
お知らせ • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024. Agenda: To consider and approve the final dividend in respect of the year ended 31 December 2023 of HK1.0 cent per share in an aggregate amount of HK$5,888,000; and to consider other matters.
お知らせ • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.
お知らせ • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024
お知らせ • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.
お知らせ • Aug 22+ 1 more updateLee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023Lee's Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Group is expected to record an unaudited net profit attributable to the Shareholders of between HKD 12 million and HKD 17 million for the six months ended 30 June 2023 as compared with approximately HKD 28 million recorded for the six months ended 30 June 2022.
お知らせ • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023
お知らせ • May 18Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive DirectorLee's Pharmaceutical Holdings Limited approved to appoint Ms. Cheang Yee Wah, Eva as the independent non-executive director of the Company, at the AGM held on 17 May 2023.
お知らせ • Jan 20Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug ListLee's Pharmaceutical Holdings Limited announce that the Group's commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the "NRDL") issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group's Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordabilityand accessibility thereof among patients in rare disease and mental health areas.
